Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
Translational Oncology · 2025-02 · 52 · 102249
DOI: 10.1016/j.tranon.2024.102249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2025-02. Verfasst von Jianfeng Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Technology Research and Development Program of Shandong Province, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Shandong Provincial Key Laboratory of Pre…
- Department of Oncology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
- Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Förderung
- Key Technology Research and Development Program of Shandong Province
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Peng, J., Zhai, X., Liu, X., Huang, Z., Wang, Y., Wu, P., Gao, R., & Meng, X. (2025). Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression. Translational Oncology, 52, 102249. https://doi.org/10.1016/j.tranon.2024.102249
Vancouver
Peng J, Zhai X, Liu X, Huang Z, Wang Y, Wu P, et al. Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression. Translational Oncology. 2025;52:102249. doi:10.1016/j.tranon.2024.102249
BibTeX
@article{Peng2025,
author = {Peng, Jianfeng and Zhai, Xueying and Liu, Xiaomei and Huang, Zhaoqin and Wang, Yimeng and Wu, Peizhu and Gao, Ran and Meng, Xiangjiao},
title = {Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression},
journal = {Translational Oncology},
year = {2025},
volume = {52},
pages = {102249},
doi = {10.1016/j.tranon.2024.102249}
}
EUVIMED